Zimmer Biomet (ZBH) to Release Quarterly Earnings on Tuesday

Zimmer Biomet (NYSE:ZBH) is expected to announce its Q1 2026 results before the market opens on Tuesday, April 28th. Analysts expect the company to announce earnings of $1.86 per share and revenue of $2.0555 billion for the quarter. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. Investors can find conference call details on the company’s upcoming Q1 2026 earning report page for the latest details on the call scheduled for Tuesday, April 28, 2026 at 8:30 AM ET.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share for the quarter, topping the consensus estimate of $2.38 by $0.04. Zimmer Biomet had a net margin of 8.56% and a return on equity of 12.93%. The firm had revenue of $2.24 billion during the quarter, compared to analysts’ expectations of $2.22 billion. During the same quarter in the prior year, the company earned $2.31 EPS. The company’s revenue was up 10.9% compared to the same quarter last year. On average, analysts expect Zimmer Biomet to post $8 EPS for the current fiscal year and $9 EPS for the next fiscal year.

Zimmer Biomet Price Performance

Shares of ZBH opened at $91.27 on Friday. Zimmer Biomet has a fifty-two week low of $84.59 and a fifty-two week high of $108.29. The company has a 50 day moving average price of $93.59 and a 200-day moving average price of $93.05. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.10 and a current ratio of 1.98. The stock has a market capitalization of $17.67 billion, a PE ratio of 25.78, a PEG ratio of 1.89 and a beta of 0.61.

Zimmer Biomet Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, April 30th. Investors of record on Tuesday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.1%. Zimmer Biomet’s dividend payout ratio is presently 27.12%.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on ZBH shares. Wells Fargo & Company increased their target price on shares of Zimmer Biomet from $93.00 to $98.00 and gave the company an “equal weight” rating in a research report on Wednesday, February 11th. Weiss Ratings raised shares of Zimmer Biomet from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Tuesday, April 7th. BTIG Research reissued a “neutral” rating on shares of Zimmer Biomet in a research report on Monday, March 23rd. Sanford C. Bernstein increased their target price on shares of Zimmer Biomet from $97.00 to $99.00 and gave the company a “market perform” rating in a research report on Friday, January 9th. Finally, TD Cowen raised shares of Zimmer Biomet from a “hold” rating to a “buy” rating in a research report on Monday, January 26th. One research analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating, twelve have assigned a Hold rating and three have given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and a consensus price target of $105.95.

Insider Transactions at Zimmer Biomet

In other Zimmer Biomet news, SVP Lori Winkler sold 2,650 shares of the company’s stock in a transaction that occurred on Thursday, March 12th. The shares were sold at an average price of $94.66, for a total transaction of $250,849.00. Following the transaction, the senior vice president owned 10,224 shares in the company, valued at approximately $967,803.84. This represents a 20.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Insiders own 1.28% of the company’s stock.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ZBH. DV Equities LLC acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth $25,000. Gen Wealth Partners Inc acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth $31,000. Headlands Technologies LLC acquired a new stake in shares of Zimmer Biomet in the second quarter worth $37,000. EFG International AG acquired a new stake in shares of Zimmer Biomet in the fourth quarter worth $55,000. Finally, Mpwm Advisory Solutions LLC acquired a new stake in shares of Zimmer Biomet in the third quarter worth $65,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.